Vertex Pharmaceuticals (VRTX) Work In Process (2011 - 2012)

Vertex Pharmaceuticals (VRTX) recorded quarterly Work In Process of $58.5 million in Q3 2012, down 1.3% quarter-over-quarter from $59.2 million in Q2 2012, and up 64.45% on a YoY basis from $35.5 million in Q4 2011.

Vertex Pharmaceuticals (VRTX) Work In Process (2011 - 2012) Analysis & Trends

Vertex Pharmaceuticals' Work In Process history runs 2 years deep, the most recent figure standing at $58.5 million for Q3 2012.

  • In Q3 2012, Work In Process rose 64.45% year-over-year to $58.5 million; the TTM figure through Sep 2012 stood at $58.5 million (up 64.45% YoY), while the FY2011 annual figure was $47.0 million, changed N/A from the prior year.
  • Work In Process was $58.5 million for Q3 2012 at Vertex Pharmaceuticals, down from $59.2 million in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $74.7 million in Q1 2012 to a low of $10.0 million in Q1 2011.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn -
7 Psyence Biomedical 212.16 Bn 212.16 Bn -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn
9 Abivax 91.96 Bn 91.96 Bn -
10 Regeneron Pharmaceuticals 63.43 Bn 54.67 Bn 3.31 Bn

Historic Data

Download Data
DateValue
Sep 30, 2012 58.45 Mn
Jun 30, 2012 59.22 Mn
Mar 31, 2012 74.74 Mn
Dec 31, 2011 47.01 Mn
Sep 30, 2011 35.54 Mn
Mar 31, 2011 10.00 Mn